Novo Nordisk taps OpenAI

Novo Nordisk is bringing OpenAI’s artificial intelligence tools into drug research, factories and sales operations as it tries to speed up new medicine development. (bloomberg.com) The Danish drugmaker announced the partnership on April 14 and said pilot projects are already running, with broader integration planned by the end of 2026. Novo said the deal includes “strict data governance” and human oversight, and it did not disclose financial terms. (biospace.com, bloomberg.com) Novo said it wants to use artificial intelligence to sift through large research datasets, spot possible drug targets, support manufacturing and help commercial teams work faster. Chief executive Mike Doustdar said millions of people with obesity and diabetes still need better treatment options. (biospace.com, cnbc.com) The move comes as Novo is leaning harder into obesity and diabetes after investors pushed it to diversify. Bloomberg reported on March 26 that the company was still prioritizing those two areas even as it lost ground to rivals in the weight-loss market. (bloomberg.com) Supply and speed have become central issues for Novo as demand for semaglutide-based medicines surged. In its 2025 annual report, the company said the United States Food and Drug Administration declared the shortage of semaglutide injectables resolved in February 2025 and said Novo was still expanding United States manufacturing capacity and strengthening its supply chain. (novonordisk.com) Novo is also trying to defend its lead in obesity drugs with new products and pricing moves. Bloomberg reported on April 1 that Novo’s Wegovy pill had topped 600,000 prescriptions after a January launch, and on March 31 that the company introduced a cash-pay subscription priced at $249 a month for the Wegovy pen. (bloomberg.com, bloomberg.com) The OpenAI agreement adds to Novo’s earlier artificial intelligence work. Bloomberg said the company already had a research-focused deal with Nvidia, while trade publication Manufacturing Chemist said the new pact widens OpenAI’s push into drugmaking after agreements involving Moderna, Eli Lilly and Sanofi with Formation Bio. (bloomberg.com, manufacturingchemist.com) For OpenAI, the pitch is not only drug discovery but company-wide adoption. Novo said the partnership includes workforce upskilling so employees can build and use tools across the business, from labs to commercial teams. (biospace.com) What happens next is less about a single chatbot than whether Novo can turn these pilots into faster research decisions, steadier production and quicker launches by December 2026. (biospace.com, bloomberg.com)